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A
 
BSTRACT
 
The airway wall of asthmatic patients is infiltrated with
inflammatory cells, consisting chiefly of eosinophils
and T lymphocytes. Among these T lymphocytes, Th2
cells are involved in the regulation of the IgE immune
response and local allergic inflammation, which
underlie allergic diseases. Various cytokines produced
and released by Th2 cells play important roles in the
development of many allergic diseases, including
asthma, and the exacerbations of their disease states.
Therefore, targeting of Th2 cell-derived cytokines is a
rational therapeutic strategy for the treatment of asthma.
Corticosteroids and immunosuppressive agents can
potently inhibit Th2 cytokine-mediated responses,
but have no selectivity for Th2 cells: they also exert
pharmacological activity against cells other than
inflammatory cells, thereby potentially causing adverse
side-effects. However, suplatast tosilate is the only spe-
cific Th2 cytokine inhibitor that can be used clinically
and it has been used widely in Japan as a main-
tenance drug in the treatment of asthma, atopic
dermatitis and allergic rhinitis. There is considerable
evidence of the effectiveness of suplatast tosilate in
patients with mild asthma or moderate persistent
asthma. Furthermore, an effect on cough variant
asthma and a steroid-sparing effect have also been
reported for suplatast tosilate.
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I
 
NTRODUCTION
 
The basic disease state of asthma is chronic airway
inflammation. The airway mucosa of asthmatic patients
is usually infiltrated with inflammatory cells, consisting
chiefly of eosinophils and T lymphocytes, and various
chemical mediators and cytokines derived from these
cells are closely involved in the pathophysiology of
asthma. In particular, Th2 cells predominate in asthma
compared with Th1 cells and activated Th2 cells
produce and release various cytokines that are involved
in the development of allergy, the aggravation of the
disease state, airway hyperresponsiveness and airway
remodeling.
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 Among these cytokines, interleukin (IL)-5
promotes the differentiation, proliferation and activation
of eosinophils and causes eosinophilic airway inflamma-
tion. In contrast, IL-4 and IL-13 stimulate B cells to
promote IgE production and enhance adhesion mole-
cule expression, mast cell proliferation and mucin secre-
tion (Fig. 1). Interleukin-9 enhances the production of
IgE, the release of chemical mediators from mast cells
and the secretion of mucin. Furthermore, based on
previously reported findings on the effects of soluble IL-4
receptor,
 
2
 
 soluble IL-13 receptor 
 
α
 
,
 
3
 
 monoclonal anti-
bodies to IL-4 and IL-5
 
4,5
 
 and gene targeting,
 
6,7
 
 the
importance of these Th2 cytokines in the allergic airway
responses has been demonstrated.
 
S
 
UPPRESSION
 
 
 
OF
 
 
 
ALLERGIC
 
 
 
INFLAMMATION
 
 
 
BY
 
 
T
 
H
 
2 
 
CYTOKINE
 
 
 
INHIBITOR
 
In Japan, in 1991, the specific Th2 cytokine inhibitor
suplatast tosilate ((+/–)-[2-[4-(3-ethoxy-2-hydroxypropoxy)
phenylcarbamoyl]ethyl]dimethylsulfonium 
 
P
 
-toluenesul-
fonate) was developed.
 
8
 
 Suplatast, at 1–5 
 
µ
 
g/mL, sup-
presses the production of IL-4 and IL-5 by a mouse Th2
clone and human Th2 cell clones specific for Japanese
cedar or 
 
Derf
 
 antigen and also suppresses the antigen-
simulated production of IL-13 by cultured basophils.
 
9,10
 
However, with regard to the production of interferon
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(IFN)-
 
γ
 
 by a purified protein derivative (PPD)-specific Th1
cell clone and murine sensitized T cells and the produc-
tion of chemokines by monocytes, suplatast is ineffective,
even at high concentrations. The Th2 cytokine-inhibitory
action of suplatast has also been confirmed 
 
in vivo
 
: in
a guinea pig model of antigen-induced asthma, a
decrease in IL-5 mRNA-expressing CD4
 
+
 
 T cells (Th2
cells) in the airway mucosa has been observed.
 
11
 
 More-
over, in patients with atopic dermatitis, the production
of IL-4 and IL-5 by peripheral blood monocytes is
increased 2 weeks after the discontinuation of steroid
administration, but the administration of suplatast inhib-
its the production of these cytokines.
 
12
 
 Although the
inhibitory activity of suplatast in Th2 cytokine production
has been confirmed at the mRNA level, its effects on
cell surface receptors and signal transduction remain
unknown and require further investigation.
 
E
 
FFECTS
 
 
 
ON
 
 
 
MILD
 
 
 
PERSISTENT
 
 
 
ASTHMA
 
The majority of evidence regarding the effects of
suplatast in the treatment of asthma concerns patients
with mild persistent asthma and the drug has been
reported to improve asthma symptoms, respiratory func-
tion, airway hyperresponsiveness and airway inflamma-
tion. Most basically, this drug is used in combination
with inhaled corticosteroids for patients with mild persist-
ent asthma patients and should be dosed chronically,
not as needed. It is considered necessary to continue the
administration of suplatast, like other anti-allergic drugs
in general, for at least 4–6 weeks to evaluate its
pharmacological effects.
In an initial uncontrolled study, Sano 
 
et al
 
.
 
13
 
 adminis-
tered 300 mg suplatast daily for 6 weeks to patients with
mild persistent asthma and showed that it improved
asthma symptoms and eosinophilic airway inflammation.
Subsequently, Sano 
 
et al.
 
 conducted a case-controlled
study
 
14
 
 and found that the suplatast-administered group
showed a gradual increase in peak expiratory flow (PEF)
and significant increases in morning and evening PEF in
the 5th and 6th weeks, as well as decreases in asthma
symptom scores, airway contractile responses to hista-
mine, the number of eosinophils, eosinophil granule-2
(EG2)-positive cells and CD4
 
+
 
 T lymphocytes in airway
biopsies, and in eosinophils and EG2-positive cells in
induced sputum (Figs 2,3).
Horiguchi 
 
et al
 
.
 
15
 
 also investigated the effects of
suplatast (300 mg/day for 4 weeks) in patients with step 1
or 2 asthma and observed an increase in morning PEF,
an improvement in airway hyperresponsiveness, a decrease
in peripheral blood eosinophils and decreases in serum
and induced sputum content of eosinophil cationic
protein (ECP). These improvements were more marked in
atopic than non-atopic patients.
We compared the effects of suplatast and an inhaled
corticosteroid in 43 adult patients with mild persistent
asthma.
 
16
 
 Subjects enrolled in the trial were step 1
patients with a forced expiratory volume in 1 s (FEV
 
1
 
) of
over 80% of the predicted value and had symptoms such
as stridor, cough and dyspnea fewer than eight times, but
 
Fig. 1
 
Pathophysiology of air-
way responses in allergic
asthma associated with Th2
cytokines released by Th2 cells.
VCAM-1, vascular cell adhesion
molecule-1; IL, interleukin; MHC,
major histocompatibility com-
plex; APC, antigen-presenting
cell.
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more than once, in the previous 1 month. In that trial,
after a 2-week run-in period, patients were divided into
three groups and each group received oral suplatast
(300 or 400 mg/day), inhaled beclomethasone dipropi-
onate (BDP; 400 
 
µ
 
g/day) or an oral placebo for 8 weeks.
During the trial, a short-acting inhaled 
 
β
 
2
 
-adrenergic
receptor agonist alone was administered concomitantly
as needed. The degree of airway inflammation was eval-
uated by eosinophil and mast cell counts in induced
sputum and the ECP and tryptase concentrations in the
sputum supernatant. As a result, as shown in Fig. 4, all
parameters decreased significantly in the suplatast- and
BDP-treated groups. These changes were observed only
in the BDP group 4 weeks after administration and BDP
tended to show an earlier anti-inflammatory effect than
suplatast, but the effect was similar in both groups
8 weeks after administration. Therefore, the effect of the
usual dose of the Th2 cytokine inhibitor for airway inflam-
mation in mild persistent asthma is equivalent to 400 
 
µ
 
g
BDP, suggesting its usefulness as an alternative or con-
current drug to inhaled corticosteroids in asthma main-
tenance therapy. In view of the fact that the prolonged
administration of inhaled steroids is associated with the
risk of systemic side-effects,
 
17–19
 
 that even short-term
administration sometimes causes local side-effects, such
as cough and laryngeal discomfort, and that oral drugs
generally have a higher compliance rate than inhalants,
suplatast should be considered as an option for the long-
term maintenance treatment of asthma.
 
E
 
FFECTS
 
 
 
ON
 
 
 
COUGH
 
 
 
VARIANT
 
 
 
ASTHMA
 
Although bronchodilators, such as 
 
β
 
2
 
-adrenergic recep-
tor agonists and theophylline are effective for the treat-
ment of cough variant asthma, recent studies have
indicated that eosinophilic airway inflammation plays an
important role in the pathogenesis of the disease;
 
20,21
 
therefore, anti-inflammatory drugs should preferentially
be chosen for treatment. Shioya 
 
et al
 
.
 
22
 
 conducted a
double-blind comparative trial of suplatast and a placebo
in 20 patients with cough variant asthma and found that
the group receiving suplatast (300 mg/day) for 6 weeks
showed no significant increase in FEV
 
1
 
 or PEF, nor any
improvement in airway hyperresponsiveness to metha-
choline. However, suplatast treatment caused decreases
in the eosinophil count and ECP content in induced
 
Fig. 2
 
(a) Changes in peak expiratory flow (PEF) observed in
the suplatast group (
 

 
, 
 

 
) and in the control group (
 

 
,
 
 
 
).
Open symbols represent morning PEF; filled symbols represent
evening PEF. (b) Changes in weekly asthma symptom scores in
the suplatast group (
 

 
) and in the control group (
 

 
).
*
 
P
 
 < 0.05, **
 
P
 
 < 0.01 compared with baseline values.
 
Fig. 3
 
Eosinophils in the induced sputum (a) before and
(b) 6 weeks after treatment with suplatast tosilate (May–Giemsa
staining; original magnification 
 
×
 
400). Arrows indicate eosi-
nophils.
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sputum by 75 and 87%, respectively. In addition, the
cough scores decreased, as did cough sensitivity to
inhaled capsaicin (Fig. 5). We speculate that the mech-
anism of these effects of suplatast probably involves
improvement of eosinophilic airway inflammation owing
to the inhibition of IL-5 production, but confirmation of
this hypothesis awaits the measurement of cytokine levels
in sputum. An improvement in the cough score was
noted in the 1st week after the administration of
suplatast, suggesting that the effect gained so early may
represent a pharmacological effect other than Th2
cytokine inhibition.
 
E
 
FFECTS
 
 
 
ON
 
 
 
MODERATE
 
 
 
TO
 
 
 
SEVERE
 
 
 
ASTHMA
 
Because the Th2 cytokine inhibitor has no bronchodilating
effect, its effect on airflow limitation in moderate to severe
asthma is weak and it is difficult to control the disease
state by suplatast monotherapy. However, because
suplatast is known to have an inhaled steroid-sparing
 
Fig. 4
 
Changes in inflamma-
tory markers of induced sputum
during 8 weeks treatment in
patients receiving suplatast
tosilate, beclomethasone dipro-
pionate or placebo. Data are
the mean 
 
±
 
 SEM. *
 
P
 
 < 0.05,
**
 
P
 
 < 0.01 compared with cor-
responding values at week 0.
ECP, eosinophil cationic protein.
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effect, this drug can be added to reduce the use of
inhaled corticosteroids at high doses for step 3–4
asthma. Tamaoki 
 
et al
 
.
 
23
 
 examined the preventive effect
of suplatast against asthma exacerbation occurring
when the dose of steroids administered was halved in
85 patients with severe asthma controlled by high doses
of BDP. As a result, a reduction in the dosage of BDP
to half resulted in lower FEV
 
1
 
 and PEF, higher asthma
symptom scores and more frequent use of a 
 
β
 
2
 
-adrenergic
receptor agonist in the placebo group, but such exacer-
bations of asthma were not observed in the suplatast
group. When the relapse of asthma was defined as a
decrease in FEV
 
1
 
 or PEF of more than 20% from
baseline or the occurrence of asthma symptoms more
than 10 times a week, the cumulative rate of steroid
reduction-induced relapse was only 13% in the suplatast
group compared with 83% in the placebo group,
showing a significant difference between the two groups
(Fig. 6).
 
E
 
VALUATION
 
 
 
OF
 
 T
 
H
 
2 
 
CYTOKINES
 
 
 
IN
 
 
 
ASTHMA
 
 
 
GUIDELINES
 
The newest guidelines for the treatment of asthma are
the Japanese Society of Allergology Guidelines for the
Diagnosis and Management of Bronchial Asthma
(JGL2003).
 
24
 
 The Th2 cytokine inhibitors are not indi-
cated for step 1 (mild intermittent) or step 2 (mild
Fig. 5 Changes in (a) cough scores and (b) cough threshold for capsaicin in patients with cough variant asthma during treatment
with placebo or suplatast tosilate. Data are the mean ± SEM. *P < 0.05 compared with corresponding values for placebo.
Fig. 6 Kaplan–Meier analysis of the probability of asthma re-
lapse during reduction of beclomethasone propionate (BDP) in
patients with severe asthma. Patients receiving suplatast tosilate
had a lower risk of relapse than those receiving placebo
(P < 0.05 by Wilcoxon single-rank test).
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persistent, including cough variant asthma) asthma as
drugs for long-term management, but are indicated for
step 3 (moderate persistent) and step 4 (severe per-
sistent) asthma as combination therapy with inhaled
corticosteroids, slow-releasing theophylline, long-acting
inhaled β2-adrenergic receptor agonists and leukotriene
antagonists. However, based on accumulated evidence,
indications for Th2 cytokine inhibitors in adult asthma
patients include: (i) mild persistent asthma (as anti-
inflammatory drugs); (ii) moderate to severe asthma
poorly controlled by usual doses of inhaled corticoster-
oids; (iii) asthma in individuals such as the elderly with
poor inhalation technique; and (iv) asthma patients
experiencing side-effects of treatment with other anti-
inflammatory drugs or steroids. Basically, this drug is
better used in combination with other anti-asthmatic
agents, except in very mild cases.
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